TransCode Therapeutics Inc.

RNAZ | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.76

+$0.11 (+6.67%)

At close: Sep 21, 2026, 4:00 PM ET

$1.84

+$0.08 (+4.55%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $1.75M

Enterprise Value $-7.73B

Beta 1.17

Average Volume 61.77K

Shares Outstanding (Diluted) 957.19K

Shares Change YoY 14.82%

Institutional Ownership 3.37%

Exchange NASDAQ

ISIN US89357L5012

Price Performance

Price Change 1M -38.7%

Price Change 3M -63.8%

Price Change 6M -79.4%

Price Change YTD -76.2%

Price Change 1Y -84.5%

Price Change 3Y -100.0%

Price Change 5Y -100.0%

1M CAGR (ann.) -61.4%

1Y CAGR (ann.) -85.5%

5Y CAGR (ann.) -93.5%

All-Time CAGR -93.6%

Valuation

PE Ratio -0.00

Forward PE N/A

PEG Ratio -0.00

Forward PEG 0.00

PS Ratio N/A

Forward PS 0.20

PB Ratio -0.00

P/FCF Ratio -0.00

P/Adj. FCF Ratio -0.00

P/OCF Ratio -0.00

EV/Sales N/A

EV/EBIT 216.99

EV/EBITDA 217.43

EV/FCF 1.55

Earnings Yield -409983.0%

FCF Yield -267874.4%

Adj. FCF Yield -262737.0%

Financial Health

Net Cash $7.73B

Total Debt $652.41M

Cash & Short-Term Investments $8.38B

Total Assets $151.01B

Current Ratio 1.97

Quick Ratio 1.97

Debt / Equity Ratio 0.00

Debt / EBITDA -18.35

Debt / FCF -0.13

OCF / Debt -7.65

Interest Coverage -5,337.75

Altman Z-Score -1.14

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -1.9%

Returns

Return on Assets -28.3%

Return on Equity -58.1%

Return on Invested Capital -23.7%

Return on Capital Employed -23.8%

Return on Tangible Assets -390.1%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y -116.8%

EPS CAGR 5Y 47.1%

EPS CAGR 10Y N/A

FCF CAGR 3Y -148.7%

FCF CAGR 5Y -98.5%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Hold

Analyst Count 0

EPS Growth Next 3Y 33.3%

Revenue Growth Next 3Y N/A

Earnings Date Nov 17, 2026

EPS Estimate (next Q) N/A

EPS Growth Est (next Q) N/A

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Cash Flow

Operating Cash Flow $-4.99B

Free Cash Flow $-4.99B

Adj. Free Cash Flow $-4.89B

FCF Per Share -$5,330.50

OCF Per Share -$5,330.50

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-28.72K

Operating Income $-27.92M

EBITDA $-35.55M

Net Income $-6.9B

EPS (Diluted) -$7,215.70

Revenue / Employee N/A

Profit / Employee $-575.1M

Employees 12